Improving MRI techniques for prostate cancer imaging

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study evaluates various technological advancements in MRI to enhance the performance of contrast-enhanced imaging used for angiography and perfusion, as well as non-contrast MRI. Participants will undergo non-contrast MRI scans, with the option for a second scan, and may also provide blood samples for analysis. The goal is to determine if these improvements can lead to better imaging outcomes for prostate neoplasm diagnosis and monitoring.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adults

Exclusion Criteria:

* Standard exclusion criteria for clinical MRI; e.g. cardiac pacemaker, claustrophobia, an implanted device that has been determined to be MR conditional at 1.5T but not at 3T, anticipated considerable susceptibility artifact from hip prosthesis, etc.

Where it's running

• Mayo Clinic in Rochester
  Rochester, Minnesota, United States Recruiting
• Mayo Clinic in Arizona
  Scottsdale, Arizona, United States Active not recruiting

Study contacts

• Principal investigator: Stephen J. Riederer, PhD — Mayo Clinic in Rochester
• Study coordinator: Clinical Trials Referral Office
• Email: mayocliniccancerstudies@mayo.edu
• Phone: 855-776-0015

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Ultrahypofractionated Proton Therapy for Localized Prostate Cancer

  This study tests whether a short course of proton beam therapy can control localized prostate cancer with acceptable safety.

  Recruiting National Cancer Center, Korea · Goyang-si, Gyeonggi-do · NCT07699705

• LY4257496 for GRPR-positive advanced breast, colorectal, prostate, and endometrial cancer (OMNIRAY)

  This Phase 1 test tries LY4257496, with GRPR imaging using LY4257529 and sometimes standard treatments, to see if it is safe and helps people with GRPR-positive advanced breast, colorectal, prostate, or endometrial cancer.

  Recruiting at 15 sites Phase 1 Eli Lilly and Company · Duarte, California and 32 other locations · NCT07114601

• Fezolinetant to reduce hot flashes in men on androgen-deprivation therapy

  This trial will test whether taking fezolinetant once daily for 4 weeks reduces how often and how severe hot flashes are in men with prostate cancer who are on androgen-deprivation therapy.

  Recruiting Phase 2 Brigham and Women's Hospital · Boston, Massachusetts · NCT06957691

• Robotic Prostatectomy Pain Reduction with Two Insufflation Devices

  This trial tests whether two different pneumoperitoneum devices used during robotic prostatectomy affect pain after surgery in men with prostate cancer.

  Recruiting East and North Hertfordshire NHS Trust · Stevenage, Hertfordshire · NCT06915909

• Using the AirSeal System for Robot-assisted Prostate Surgery

  This study tests if using the AirSeal system during robot-assisted prostate surgery can lead to better results, like shorter hospital stays and fewer complications, for men with prostate cancer compared to traditional methods.

  Recruiting at 2 sites Phase 4 Brazilian Institute of Robotic Surgery · Salvador, Estado de Bahia and 1 other locations · NCT06784986

• Understanding how obesity-related factors influence prostate cancer progression

  This study looks at how being overweight or obese affects prostate cancer by checking certain enzymes and immune cells in tumor samples from patients with different body weights.

  Recruiting Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · Milan · NCT06292897

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.